Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Amarin Corporation plcNASDAQ: AMRN
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $14.82M (cash outflow) fell 15.5% year over year, behind the +128.8% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 6.8% of revenue in FY2025, down 26.9 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -15.5% toward the trailing-twelve-month pace of +128.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 14.54M USD
- Year-over-year change
- +118.9%
- 4-year CAGR
- -27.1%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.54M | +118.9% |
| FY2024 | 2024-12-31 | (77.02M) | -46681.7% |
| FY2023 | 2023-12-31 | (164.64K) | +99.8% |
| FY2022 | 2022-12-31 | (102.67M) | -299.3% |
| FY2021 | 2021-12-31 | 51.51M | — |
Accounts Payables vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +128.8% is the 4th highest of 9, against a peer median of +22.0%.
- Accounts payables amounts to 8.0% of revenue for AMRN, versus a peer median of 337.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.22M USD | +128.8% | — | 8.0% | |
| LTM Mar 2026 | $5.87M USD | +736.9% | +375.3% | — | |
| LTM Mar 2026 | $5.6M USD | — | — | 608.1% | |
| LTM Mar 2026 | $4.34M USD | -72.9% | +66.1% | — | |
| LTM Mar 2026 | $2.56M USD | -290.8% | — | 66.7% | |
| LTM Mar 2026 | $1.98M USD | +327.2% | -39.7% | — | |
| LTM Mar 2026 | $1.7M USD | +135.6% | — | 5477.4% | |
| LTM Mar 2026 | $1.34M USD | -181.1% | — | 2.0% | |
| LTM Mar 2026 | $453K USD | +116.9% | -3.3% | 1258.3% | |
| LTM Dec 2025 | CHF 327.34K CHF | — | — | 9.2% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $105K USD | -108.0% | — | — |
| Peer median (excluding AMRN) | — | +22.0% | +31.4% | 337.4% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.73M | (105.74M) | (59.34M) | (82.18M) | (38.8M) |
| Depreciation & Amortization | 2.86M | 3.09M | 2.98M | 3.01M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 17.71M | 13.94M |
| Change in Working Capital | (115.98M) | (104.01M) | 51.27M | 36.17M | 32.28M |
| Accounts Receivables | (8.34M) | 32.98M | (2.33M) | 11.22M | (3.83M) |
| Inventory | (167.05M) | (36.4M) | 56.34M | 105.44M | 34.96M |
| Accounts Payables | 51.51M | (102.67M) | (164.64K) | (77.02M) | 14.54M |
| Other Working Capital | 7.9M | 2.07M | (2.56M) | (3.5M) | (13.39M) |
| Other Non-Cash Items | 38.86M | 26.67M | 12M | (5.73M) | (3.71M) |
| Operating Cash Flow | (66.53M) | (179.98M) | 6.91M | (31.03M) | 6.74M |
| Capital Expenditures | 2 | (2) | (24.1K) | 2 | 0 |
| Acquisitions (Net) | 4K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (290.16M) | (81.58M) | (215.93M) | (278.78M) | (200.94M) |
| Sales of Investments | 394.25M | 257.36M | 190.84M | 232.8M | 209.79M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 104.09M | 175.18M | (25.62M) | (45.98M) | 8.85M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 4.57M | 664.59K | 2.22M | 131.06K | 140.33K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.64M) | (1.04M) | (1.99M) | (1.57M) | (2.18M) |
| Financing Cash Flow | (5.07M) | (378.77K) | 230.89K | (1.44M) | (2.04M) |
| Effect of Forex Changes | 3.87K | (3.2K) | 71.37K | 33.01K | (31.6K) |
| Net Change in Cash | 32.49M | (5.18M) | (18.41M) | (78.44M) | 13.52M |
| Free Cash Flow | (66.53M) | (179.98M) | 6.88M | (31.02M) | 6.74M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.